HELLS also promotes the development of pancreatic cancer through epigenetic silencing of the tumor suppressor TGFBR3, whereas inhibition of HELLS slows tumor growth and increases sensitivity to the chemotherapeutic agent cisplatin. This evidence concerns the gene TGFBR3 and pancreatic neoplasm.